successfully employed BRAF-MEK inhibitors, specifically dabrafenib and trametinib, in the treatment of an infantile DIG presenting with leptomeningeal brainstem dissemination, this treatment approach resulted in a reduction of both residual tumor size and leptomeningeal disease burden (21). This evidence concerns the gene MAP2K7 and neoplasm.